BNP Paribas Financial Markets’s ImmunityBio IBRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $825K | Sell |
94,282
-15,195
| -14% | -$115K | ﹤0.01% | 3446 |
|
|
2026
Q1 | $840K | Buy |
109,477
+70,505
| +181% | +$483K | ﹤0.01% | 3262 |
|
|
2025
Q4 | $77.2K | Sell |
38,972
-16,033
| -29% | -$36.3K | ﹤0.01% | 4482 |
|
|
2025
Q3 | $135K | Buy |
55,005
+22,870
| +71% | +$58.9K | ﹤0.01% | 4179 |
|
|
2025
Q2 | $84.8K | Buy |
32,135
+14,643
| +84% | +$39.4K | ﹤0.01% | 4071 |
|
|
2025
Q1 | $52.7K | Sell |
17,492
-17,496
| -50% | -$53K | ﹤0.01% | 4276 |
|
|
2024
Q4 | $89.6K | Buy |
+34,988
| New | +$146K | ﹤0.01% | 4193 |
|
|
2022
Q4 | – | Sell |
-148,282
| Closed | -$737K | – | 4297 |
|
|
2022
Q3 | $737K | Buy |
+148,282
| New | +$676K | ﹤0.01% | 2704 |
|
|
2021
Q1 | – | Sell |
-6,256
| Closed | -$83.4K | – | 4065 |
|
|
2020
Q4 | $83.4K | Sell |
6,256
-975
| -13% | -$9.38K | ﹤0.01% | 3303 |
|
|
2020
Q3 | $50.1K | Buy |
7,231
+6,070
| +523% | +$60.5K | ﹤0.01% | 3471 |
|
|
2020
Q2 | $14.3K | Buy |
1,161
+1,077
| +1,282% | +$6.08K | ﹤0.01% | 3548 |
|
|
2020
Q1 | $242 | Sell |
84
-151
| -64% | -$756 | ﹤0.01% | 4174 |
|
|
2019
Q4 | $891 | Sell |
235
-3,071
| -93% | -$5.23K | ﹤0.01% | 4231 |
|
|
2019
Q3 | $4.03K | Hold |
3,306
| – | – | ﹤0.01% | 4296 |
|
|
2019
Q2 | $3.37K | Sell |
3,306
-2,742
| -45% | -$3.16K | ﹤0.01% | 4283 |
|
|
2019
Q1 | $9.56K | Buy |
6,048
+3,252
| +116% | +$4.08K | ﹤0.01% | 4028 |
|
|
2018
Q4 | $3.24K | Buy |
2,796
+1,783
| +176% | +$4.08K | ﹤0.01% | 3710 |
|
|
2018
Q3 | $3.75K | Hold |
1,013
| – | – | ﹤0.01% | 4148 |
|
|
2018
Q2 | $3.1K | Sell |
1,013
-4,971
| -83% | -$18.4K | ﹤0.01% | 4201 |
|
|
2018
Q1 | $23.3K | Buy |
5,984
+113
| +2% | +$495 | ﹤0.01% | 3887 |
|
|
2017
Q4 | $26.4K | Buy |
5,871
+2,832
| +93% | +$13.4K | ﹤0.01% | 3910 |
|
|
2017
Q3 | $16.7K | Sell |
3,039
-176
| -5% | -$1.08K | ﹤0.01% | 3685 |
|
|
2017
Q2 | $24.4K | Buy |
3,215
+2,736
| +571% | +$11.8K | ﹤0.01% | 3548 |
|
|
2017
Q1 | $1.7K | Sell |
479
-134
| -22% | -$662 | ﹤0.01% | 3577 |
|
|
2016
Q4 | $3.51K | Sell |
613
-881
| -59% | -$5.88K | ﹤0.01% | 3817 |
|
|
2016
Q3 | $11.6K | Sell |
1,494
-12
| -0.8% | -$90 | ﹤0.01% | 3124 |
|
|
2016
Q2 | $9.37K | Buy |
1,506
+1,446
| +2,410% | +$11.2K | ﹤0.01% | 2942 |
|
|
2016
Q1 | $493 | Sell |
60
-547
| -90% | -$5.16K | ﹤0.01% | 2562 |
|
|
2015
Q4 | $10.5K | Sell |
607
-628
| -51% | -$9.32K | ﹤0.01% | 3219 |
|
|
2015
Q3 | $14.2K | Buy |
+1,235
| New | +$27K | ﹤0.01% | 3380 |
|
Other funds holding IBRX
BNP Paribas Financial Markets's IBRX Position: Q2 2026 in Review
BNP Paribas Financial Markets reduced its ImmunityBio (IBRX) stake by 14% in Q2 2026, selling an estimated $115K and leaving 94,282 shares worth $825K. The position accounts for ﹤0.01% of the portfolio, ranked #3446.
BNP Paribas Financial Markets first reported a position in IBRX in Q3 2015 and has held it in 30 quarters since. The position peaked at $840K in Q1 2026. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.
- BNP Paribas Financial Markets held 94,282 shares of ImmunityBio worth $825K as of Q2 2026.
- BNP Paribas Financial Markets sold 15,195 ImmunityBio shares in Q2 2026, an estimated $115K.
- ImmunityBio made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #3446 holding.
- BNP Paribas Financial Markets first reported a position in ImmunityBio in Q3 2015 and has held it in 30 quarters since.
- BNP Paribas Financial Markets's ImmunityBio position peaked at $840K in Q1 2026.
- 404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.